Efficacy of Hepatic Artery Infusion Chemotherapy with Bevacizumab and Sintilimab in Advanced Hepatocellular Carcinoma: A Case Report., PMID:40481624
Electrochemical surface plasmon resonance based biosensor for α-fetoprotein detection via different coupling strategies., PMID:40374766
Porous platinum nanozyme-amplified capacitance immunoassay for alpha-fetoprotein with hepatocellular carcinoma on an interdigitated gold micro-comb array., PMID:40374253
Potential Roles of Serum Exosomal CD155 and its Impact on NK Cell Immunosuppression in Hepatocellular Carcinoma., PMID:40326845
Facile Immunoassay Constructed by Gold Nanostar-Labeled Rabbit-AFP Antibody and Gold Nanoparticle-Conjugated Goat Anti-Rabbit IgG., PMID:40278477
Application of immunofluorescence-based detection of AFP-L3 in the diagnosis of hepatocellular carcinoma., PMID:40258775
Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG)., PMID:40241388
Alpha-Fetoprotein (AFP) biosensors., PMID:40216053
Cell Therapy Using Anti-NKG2A Pretreated Natural Killer Cells in Patients with Hepatocellular Carcinoma., PMID:40190667
PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial., PMID:40082418
[Exploration of biomarkers for the efficacy of anti-PD-1 immunotherapy in patients with gastric cancer peritoneal metastasis]., PMID:40069088
Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study., PMID:40055288
Construction of electrochemical immunosensor by integrating N, S doped carbon dots with Fe2O3 for ultrasensitive sensing alpha-fetoprotein., PMID:40054220
Application of Indirect ELISA and PCR Techniques for Detecting of Hepatocellular Carcinoma using Des-gamma Carboxyprothrombin, Alpha-fetoprotein, and Thioredoxin Biomarkers., PMID:39998774
Application of CT-based radiomics combined with laboratory tests such as AFP and PIVKA-II in preoperative prediction of pathologic grade of hepatocellular carcinoma., PMID:39962429
Rapid Detection of Alpha-Fetoprotein (AFP) with Lateral Flow Aptasensor., PMID:39942588
Case report: Chemotherapy plus sintilimab for the treatment of gastroesophageal junction hepatoid adenocarcinoma with liver metastasis: a case study with literature review., PMID:39931054
Direct repeat region 3' end modifications regulate Cas12a activity and expand its applications., PMID:39883010
Neutralizing antibody landscape of the non-polio Enteroviruses and future strategy., PMID:39877351
Clinical features of abnormal α-fetoprotein in 15 patients with chronic viral hepatitis B after treatment with antiviral drugs., PMID:39871898
Subtype-specific human endogenous retrovirus K102 envelope protein is a novel serum immunosuppressive biomarker of cancer., PMID:39850893
A proteomic atlas of glypican-3 interacting partners: Identification of alpha-fetoprotein and other extracellular proteins as potential immunotherapy targets in liver cancer., PMID:39822733
Are Ki-67 and Procalcitonin Expression Levels Useful in Predicting the Biological Behavior of Hepatocellular Carcinoma After Liver Transplantation?, PMID:39797227
Reliable Performance of mALBI Grade-Based Risk Models for Predicting the Prognosis of Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab as First-Line Treatment: Comparative Analysis of 13 Risk Models., PMID:39762722
Leveraging self-signal amplifying poly(acrylic acid)/polyaniline electrodes for label-free electrochemical immunoassays in protein biomarker detection., PMID:39742710
Establishment and Application of a Dual Immunoassay Method Based on ICP-MS for Stable Element Labeling Antibodies., PMID:39739525
The CRAFITY score emerges as a paramount prognostic indicator in hepatocellular carcinoma patients received Lenvatinib and Pembrolizumab., PMID:39555053
Case report: Significant response of alpha-fetoprotein-producing gastric cancer from combined chemotherapy and immunotherapy., PMID:39530092
Use of Modified Multiplier of the Simple Endoscopic Score for Crohn's Disease Endoscopic Improvement Thresholds Enhances Effect Size Differentiation Between Adalimumab Versus Placebo: A Post Hoc Analysis of the EXTEND Trial., PMID:39529369
Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study., PMID:39499356
Screening of Cancer-Specific Biomarkers for Hepatitis B-Related Hepatocellular Carcinoma Based on a Proteome Microarray., PMID:39489219
An ingenious electrochemical system based on naphthalenediimide derivatives for ultrasensitive immunosensing of alpha-fetoprotein., PMID:39488157
Characteristics and Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab Combination Therapy Who Achieved Complete Response., PMID:39451767
A case of complete response to radiotherapy combined with durvalumab and tremelimumab in a patient with unknown primary hepatocellular carcinoma arising in the lumbar spine., PMID:39446307
Tissue and Imaging Biomarkers of Response to Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Patients with Resectable Hepatocellular Carcinoma., PMID:39427654
Transarterial chemoembolization combined with lenvatinib plus tislelizumab for unresectable hepatocellular carcinoma: a multicenter cohort study., PMID:39411718
Electrochemical immunosensor based on PtNPs/MoS2@rGO composite for the detection of alpha-fetoprotein in human serum., PMID:39387898
Ultrasensitive lab-on-paper electrochemical device via heterostructure copper/cuprous sulfide@N-doped C@Au hollow nanoboxes as signal amplifier for alpha-fetoprotein detection., PMID:39368293
Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy., PMID:39321197
Outcomes of Patients With Prior Biologic Intolerance Are Better Than Those With Biologic Failure in Clinical Trials of Inflammatory Bowel Disease., PMID:39302135
A chemiluminescence immunosensor for biomarker detection based on boronic acid-modified magnetic composite microspheres., PMID:39301709
CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective study., PMID:39289234
Universal sulfatase-based chemiluminescence biosensing platform: Validation via AFP detection in clinical blood samples., PMID:39265427
Cu-MOFs@AuPtNPs nanozyme-based immunosorbent assay for colorimetric detection of alpha-fetoprotein., PMID:39225244
Risk predictive model for the development of hepatocellular carcinoma before initiating long-term antiviral therapy in patients with chronic hepatitis B virus infection., PMID:39206860
Early Changes in Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin Are Useful Predictors of Antitumor Response to Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma., PMID:39195298
Labeled sandwich-type electrochemical immunosensor based on Ti3C2Tx/AuNP and Ti3C2Tx/HKUST-1/TB composites for early liver cancer detection., PMID:39192061
Ionic liquid-reinforced Hydroxyapatite@nano-TiO2 as a green platform for Immuno-electrochemical sensing applications., PMID:39128315
Exploring novel circulating biomarkers for liver cancer through extracellular vesicle characterization with infrared spectroscopy and plasmonics., PMID:39122286
BALAD score predicts the recurrence and survival in the patients who underwent initial hepatectomy for HCC., PMID:39029425
For research use only. Not for human or drug use.
